Failures of Realignment Osteotomy

Manuel F. Schubert(Stanford University), Seth L. Sherman(Stanford University), Alan Getgood(Western University), R. Sidhu(McMaster University)

Operative Techniques in Sports Medicine

December 28, 2019

10.1016/j.otsm.2019.150714

Cited by 3

Related Papers

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

|Annals of Oncology|2014|603

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

|Annals of Oncology|2013|220

Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel?

|Alimentary Pharmacology & Therapeutics|2010|57

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

|Annals of Oncology|2016|46

Low rates of serious complications but high rates of hardware removal after high tibial osteotomy with Tomofix locking plate

|Knee Surgery Sports Traumatology Arthroscopy|2020|42